Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Achaogen Inc (AKAO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 912,998
  • Shares Outstanding, K 40,850
  • Annual Sales, $ 41,770 K
  • Annual Income, $ -71,230 K
  • 36-Month Beta 1.67
  • Price/Sales 21.99
  • Price/Cash Flow 0.00
  • Price/Book 10.25

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.50 +14.62%
on 05/31/17
26.50 -15.66%
on 05/24/17
-3.73 (-14.30%)
since 05/23/17
3-Month
19.50 +14.62%
on 05/31/17
27.49 -18.70%
on 05/17/17
+2.05 (+10.10%)
since 03/23/17
52-Week
3.36 +565.18%
on 07/15/16
27.79 -19.58%
on 03/13/17
+18.36 (+460.15%)
since 06/23/16

Most Recent Stories

More News
Achaogen Announces New Employment Inducement Grants

Achaogen, Inc. (NASDAQ: AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on June 20,...

AKAO : 22.35 (-0.62%)
Achaogen Highlights Data Demonstrating Potential of Plazomicin Against MDR Gram-Negative Bacteria at ASM Microbe 2017 Annual Meeting

-- Oral presentations highlighted data from plazomicin Phase 3 EPIC and CARE clinical trials --

AKAO : 22.35 (-0.62%)
Achaogen Initiates C-Scape Clinical Development Program with Phase 1 Study of Orally-Administered Antibacterial Candidate

-- Clinical trial to evaluate orally-administered beta-lactam/beta-lactamase inhibitor combination being developed for infections due to extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae...

AKAO : 22.35 (-0.62%)
Research Reports Coverage on Biotech Stocks -- Achaogen, Bellicum Pharma, Coherus BioSciences, and Conatus Pharma

On Wednesday, the NASDAQ Composite ended the day at 6,198.52, down 0.08%; the Dow Jones Industrial Average edged 0.10% lower, to finish at 21,008.65; and the S&P 500 closed at 2,411.80, slightly slipping...

CNAT : 5.10 (+2.82%)
AKAO : 22.35 (-0.62%)
CHRS : 15.65 (-0.95%)
BLCM : 13.39 (-4.22%)
Achaogen Announces Pricing of Public Offering of Common Stock

Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced...

AKAO : 22.35 (-0.62%)
Achaogen's Plazomicin Gets Breakthrough Therapy Designation

Achaogen, Inc. (AKAO) announced that the FDA granted Breakthrough Therapy designation for plazomicin, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant...

AGLE : 3.58 (-9.37%)
VVUS : 1.22 (+5.17%)
AKAO : 22.35 (-0.62%)
MEIP : 2.30 (+6.48%)
Plazomicin Granted FDA Breakthrough Therapy Designation

Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the U.S. Food...

AKAO : 22.35 (-0.62%)
Achaogen Announces Proposed Public Offering of Common Stock

Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced...

AKAO : 22.35 (-0.62%)
Achaogen Reports First Quarter 2017 Financial Results and Provides Corporate Update

-- Presented additional Phase 3 EPIC and CARE trial data highlighting the safety and efficacy of plazomicin during late-breaker session at ECCMID --

AKAO : 22.35 (-0.62%)
Investor Network: Achaogen, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 8, 2017 / Achaogen, Inc. (NASDAQ: AKAO) will be discussing their earnings results in their Q1 Earnings Call to be held May 8, 2017 at 4:30 PM Eastern Time.

AKAO : 22.35 (-0.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment...

See More

Support & Resistance

2nd Resistance Point 23.22
1st Resistance Point 22.79
Last Price 22.35
1st Support Level 21.69
2nd Support Level 21.02

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.